Stryker Corporation
Stryker Corporation (SYK) is a global medical‑technology company best known for orthopaedics, surgical equipment, neurotechnology and patient-handling systems. Investors should know it sells high-margin implants, powered surgical tools and capital equipment to hospitals and clinics, giving it exposure to both recurring consumable sales and larger, cyclical procedure volumes. Growth drivers include an ageing population, innovation in implants and minimally invasive procedures, geographic expansion and selective acquisitions. Key considerations are sensitivity to elective-surgery cycles, hospital capital spending and regulatory approvals; reimbursement policies and competition from other device makers can also affect results. Stryker has a track record of reinvesting in R&D, pursuing M&A and returning cash to shareholders, but margins and growth rates can vary over time. This is general, educational information only — not personal investment advice. Values can rise and fall and past performance is not a reliable guide. Suitability depends on your circumstances; consider seeking regulated financial advice before investing.
Why It's Moving
Stryker Gears Up for Pivotal Q4 Earnings Reveal as Shares Dip Ahead of Key Data Drop.
- Q3 2025 revenue surged to $6.1B, up 10.25% year-over-year, underscoring robust demand for innovative medical tech solutions.
- Earnings release on January 29 will detail full-year results ending December 31, 2025, with a webcast to unpack strategy and outlook.
- Recent insider activity shows 26 sales and zero buys over six months, signaling executives trimming positions amid high valuations.
Stryker Gears Up for Pivotal Q4 Earnings Reveal as Shares Dip Ahead of Key Data Drop.
- Q3 2025 revenue surged to $6.1B, up 10.25% year-over-year, underscoring robust demand for innovative medical tech solutions.
- Earnings release on January 29 will detail full-year results ending December 31, 2025, with a webcast to unpack strategy and outlook.
- Recent insider activity shows 26 sales and zero buys over six months, signaling executives trimming positions amid high valuations.
When is the next earnings date for Stryker Corporation (SYK)?
Stryker (SYK) is scheduled to report its next earnings for the fourth quarter and full year 2025 after market close on Thursday, January 29, 2026. This date aligns with the company's official announcement and consensus from multiple analyst projections. The earnings webcast is set for 4:30 p.m. ET on the same day.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Stryker's stock, anticipating it could rise to $432.43.
Financial Health
Stryker Corporation demonstrates strong cash flow, revenue, and profitability, indicating solid financial performance.
Dividend
Stryker's dividend yield of 0.96% is low, indicating limited income for investors seeking dividends. If you invested $1000, you would be paid $9.60 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SYK
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Elective Surgery Exposure
Stryker benefits from demand for joint replacements and minimally invasive procedures, though revenues can move with surgical volumes and economic cycles.
Innovation and M&A
Regular new-product launches and selective acquisitions can extend market share, but integration and regulatory approval carry execution risk.
Global Footprint
Diversified geographic presence helps growth and resilience, though it brings exposure to local reimbursement policies and currency fluctuations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
